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Many  in  the  scientiﬁc  community  agree  that  a randomized,  placebo-controlled  trial  would  offer  the  most
scientiﬁcally  rigorous  study  design  for establishing  the  efﬁcacy  of  a Group  B Streptococcus  (GBS)  vaccine
administered  to  pregnant  women  for the prevention  of  invasive  GBS  disease  in  young  infants.  There  are
compelling  reasons  to conduct  such  a  trial in  low-middle  income  countries  (LMICs)  with  a high  burden
of disease,  such  as  South  Africa, and  to adopt  an  add-on  trial design  in  which  participants  are  randomized
to  receive  the  GBS  vaccine  or placebo  in  addition  to  the  locally  available  standard  of care.  Yet  there  is a
longstanding  debate  about  whether  trials  in  LMICs  should  offer  participants  the  worldwide  best  available
standard  of  care.  In this  article,  we  examine  both  the  risk–beneﬁt  proﬁle  and the  potential  for  exploitation
with  an  add-on  trial  design  in  the  context  of  the locally  available  standard  of care  in South  Africa.  Our
analysis  suggests  that providing  the  local  standard  of  care  to  participants  in  this case  may  be  not  only
more  scientiﬁcally  valuable  but  also  more  ethically  acceptable  than  attempting  to provide  the  worldwide
best  available  standard  of care  in  the South  African  setting.  Moreover,  the example  of  GBS  in the  South
African  setting  can  help  to  elucidate  important  ethical  considerations  for  determining  the  acceptability
of  testing  vaccine  efﬁcacy  in  the  context  of  locally  available  rather  than  the  worldwide  best  available
standard  of  care  in Phase  III  trials  of other  new  maternal  vaccines.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Many in the scientiﬁc community agree that a randomized,
lacebo-controlled trial would offer the most scientiﬁcally rigorous
tudy design for establishing the efﬁcacy of a Group B Streptococcus
GBS) vaccine administered to pregnant women for the prevention
f invasive GBS disease in young infants [1]. There are compelling
easons to conduct such a trial in low-middle income countries
LMICs) such as South Africa, due in part to the high burden of dis-
ase, and to adopt an add-on trial design in which participants are
andomized to receive the GBS vaccine or placebo in addition to
he locally available standard of care. Yet there is a longstanding
ebate about whether trials in LMICs should offer participants the
 The views expressed are the authors’ and do not represent the views or poli-
ies of the NIH, Department of Health and Human Services, or the United States
overnment.
∗ Corresponding author at: NIH Department of Bioethics, 10 Center Drive, 1C118,
ethesda, MD 20892-1156, USA. Tel.: +1 301 496 2429.
E-mail address: Amina.white@nih.gov (A. White).
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.108
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
worldwide best available standard of care [2]. In this article, we
examine both the risk–beneﬁt proﬁle and the potential for exploita-
tion with an add-on trial design in the context of the locally
available standard of care in South Africa. Our analysis suggests
that providing the local standard of care to participants in this case
may  be not only more scientiﬁcally valuable but also more ethically
acceptable than attempting to provide the worldwide best avail-
able standard of care in the South African setting. Moreover, the
example of GBS in the South African setting can help to elucidate
important ethical considerations for determining the acceptability
of testing vaccine efﬁcacy in the context of locally available rather
than the worldwide best available standard of care in Phase III trials
of other new maternal vaccines.
2. BackgroundDespite a 36% decline in global under-5 childhood mortality over
the past decade, the number of deaths occurring during the ﬁrst
month of life has remained high [3]. In 2013, 44% of all under-5
child deaths occurred during the ﬁrst month of life, approximately
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ne-third of which were attributable to infectious causes [3]. The
otential to reduce neonatal mortality from infectious diseases by
mmunizing women during pregnancy to provide antibody pro-
ection to their newborns is evident from the tetanus vaccination
rogram targeted at pregnant women, which has contributed to a
.5% year-on-year decline in neonatal tetanus-related deaths in the
ast decade [4]. The success of maternal vaccination is now being
xplored for the prevention of other infections affecting neonates
nd young infants, prompting the development of new vaccines
or use in the third trimester of pregnancy in expectant mothers to
rovide passive immunity to their newborns.
Ongoing efforts have been aimed at developing a maternal vac-
ine against GBS, which remains the leading cause of neonatal
epsis and meningitis in many countries [5]. Asymptomatic vaginal
olonization of GBS occurs in roughly 12–27% of pregnant women
orldwide [5]. In addition to being a possible cause for stillbirth and
aternal intrauterine infection, it results in 50% perinatal trans-
ission to newborns, leading to early onset (EOD; 0–6 days of age)
nvasive disease in 1–2% of colonized newborns [6]. Global case
atality rates reported in a recent meta-analysis range from a mean
f less than 1% in Europe to as high as 22% in parts of Africa [7].
outh Africa and many other African countries report the highest
revailing incidence of invasive GBS globally [7].
Although effective strategies already exist for prevention of
arly-onset GBS disease, current approaches are far from optimal.
ased on studies showing a more than 80% reduction in preventing
arly-onset disease (EOD; within 7 days of life), the best possible
revention involves screening pregnant women at 35–37 weeks
estation for recto-vaginal colonization, with targeted intrapartum
ntibiotic prophylaxis (IAP) given to colonized women during labor
6,8,9]. Yet this strategy has not been effective in preventing late-
nset disease (LOD; 7–90 days of life), which represents up to
ne-third of cases in regions without an IAP program and the major-
ty of disease in settings where screening-based IAP programs exist
6,8].
Moreover, this universal screening strategy, which is the
tandard of care in some high-income countries, is resource
ntensive and logistically challenging or impractical in other high-
ncome countries and most LMICs. In addition to citing the low
ost-effectiveness of screening all women prior to the onset
f labor, countries that have not adopted universal screening
ave raised concerns about overexposure to antibiotics leading
o higher rates of antibiotic resistance, an over-medicalization
f labor, uncertainties about the strength of available evidence
n the absence of well-conducted randomized trials, and logis-
ical difﬁculties screening and treating large populations of
omen delivering at home rather than in a hospital setting [9].
any countries, including the United Kingdom, have therefore
dopted a more targeted risk-based approach in which intrapartum
ntibiotics are speciﬁcally directed to women with established
isk-factors for invasive disease in their newborns. These mater-
al risk-factors associated with EOD include intra-partum fever,
upture of amniotic sac membranes prior to onset of labor or >18 h
rior to birth of the child, presence of chorio-amnionitis, history of
BS bacteriuria during pregnancy and preterm labor [10]. Although
here is evidence to suggest that universal screening is more effec-
ive than the risk-based approach for preventing early-onset GBS
isease, the drawbacks of screening have fuelled debate about what
ecommendations are most appropriate in each country [9].
Both the lack of effectiveness of IAP in preventing late onset
isease and the logistical challenges of implementing widespread
creening for GBS at 35–37 weeks gestation suggest the need for
dditional prevention strategies. A conjugate GBS vaccine holds
uch promise for meeting this need. The vaccine has the poten-
ial to reduce the incidence of not only early-onset disease but
lso late-onset disease. GBS vaccination of pregnant women  would 33 (2015) 6396–6400 6397
ideally become the primary preventative strategy for control of EOD
and replace the need for antepartum universal screening and IAP in
most cases. However, as optimal transplacental transfer of antibody
to the fetus only matures at approximately 34 weeks of gestational
age, maternal vaccination may not protect preterm neonates born
at earlier gestational ages. Due to the increased risk of invasive GBS
disease in premature births, which is partly mitigated by providing
IAP to mothers in preterm labor, IAP may  still be necessary despite
maternal GBS vaccination for some women  with EOD risk factors.
Nonetheless, an effective vaccine would prevent the vast major-
ity of EOD cases and substantially reduce poor neonatal outcomes
attributable to early invasive disease.
The likelihood of maternal GBS vaccination preventing LOD
will depend on the magnitude of the antibody response induced
by vaccination, transplacental (and possibly breast milk) transfer
thereof to the newborn and kinetics of the antibody response in
the neonate. As the majority of LOD cases occur within the ﬁrst
month of life, including a median age of 14 days for LOD  in South
Africa, it is highly plausible that maternal GBS vaccination would
protect against EOD and the majority of LOD [11].
Furthermore, vaccination could also provide protection against
pregnancy complications and offer direct beneﬁts to mothers. GBS
has been implicated as a risk factor for preterm births and still-
births [12–14]. An effective vaccine could potentially reduce the
risk of these poor obstetrical outcomes attributable to mater-
nal GBS colonization. It may  also provide direct beneﬁts to
pregnant women themselves, as GBS is known to cause urinary
tract infections, chorioamnionitis, postpartum endometritis, bac-
teremia, septic abortion, meningitis, and other serious infections
[15]. Thus, demonstrating the efﬁcacy of a GBS vaccine offers mater-
nal and pregnancy-related beneﬁts that could improve outcomes
for women  and infants in high-income countries as well as LMICs.
The availability of an effective vaccine would be particularly
valuable in a middle-income country like South Africa, which has
seen a persistently high incidence of invasive GBS disease despite
the standard of care being the same targeted risk-based IAP strategy
as the standard of care in the United Kingdom. The persistent high
burden of disease in LMICs like South Africa relates to the resource
constraints of infrastructure to conduct microbiological evaluations
and coordinate the return of results to facilities where women actu-
ally deliver, which could be unpredictable. Likewise, infrastructure
is often lacking to ensure the timely administration of antibiotics for
the recommended four hours prior to delivery and to provide any
antibiotic coverage for the deliveries occurring outside of health
facilities. In a recent cost-effectiveness analysis, Kim and colleagues
projected that if a vaccine is 50–90% efﬁcacious and 75% of pregnant
women are vaccinated in South Africa, GBS vaccination alone would
prevent 30–54% of infant GBS invasive cases compared to the 10%
reduction from the current risk-based antibiotic standard of care.
In absolute numbers, this would amount to the yearly prevention
of 2912–5260 cases and 516–934 deaths attributable to GBS at a
high level of cost-effectiveness [16]. Given these projections, a vac-
cine strategy would be more logistically feasible and sustainable
than universal screening. The vaccine would likely only need to be
given sometime in the third trimester, could be administered by
semi-skilled health workers, and is not subject to the challenges
of screening or antibiotic administration. Evidence of the practi-
cality of maternal vaccination is partly based on the experience of
maternal tetanus vaccination acceptability and its contribution to
reducing neonatal tetanus even in low income settings [17]. A trial
demonstrating the efﬁcacy of a GBS vaccine would thus be highly
valuable in settings like South Africa.Phase I/II trials of a trivalent GBS vaccine have now been con-
ducted, and in the absence of a recognized serological correlate
of protection acceptable by regulatory authorities for licensure
based on safety and immunogenicity, a Phase III trial to determine
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accine efﬁcacy against invasive GBS disease is now warranted.
egulatory authorities are currently being engaged to determine
he endpoints for a Phase III GBS trial. While ideally these end-
oints should establish efﬁcacy against invasive GBS disease, study
ndpoints measuring safety and establishing serological correlates
f protection are also important for licensure. Notably, if the pivotal
BS efﬁcacy study is undertaken in a LMIC setting, then uncertainty
bout whether the vaccine will be equally effective in a high income
etting will likely impact licensure of the vaccine in high income
ountries. For this reason, designing a Phase III trial that focuses
rimarily on maternal, fetal and infant safety as the main end-
oint and also establishes a serologic correlate of protection could
e particularly useful. Whereas a deﬁnitive serological correlate of
rotection against invasive GBS disease is yet to be established,
ncluding the development of a standardized assay, epidemiolog-
cal studies strongly support the association of capsular serotype
ntibody protecting against homotypic serotype invasive disease in
eonates [18]. Demonstrating GBS vaccine efﬁcacy in a LMIC setting
nd establishing serologic correlates of protection could follow a
rajectory similar to the pneumococcal conjugate vaccine, as subse-
uent new formulations were licensed solely on the basis of safety
nd immunogenicity [19]. Bridging studies of safety and immuno-
enicity could then be conducted along with obligatory Phase IV
tudies in high income countries to support licensure of the GBS
accine in those countries. Attention to the Phase III trial design is
herefore critical in facilitating the eventual delivery of an effective
BS vaccine to the various countries where it may  be valuable.
A randomized, placebo-controlled trial of vaccine efﬁcacy would
rovide the level of scientiﬁc evidence necessary to inform local
linical practice and public health guidelines where the study is
onducted [1]. One possible trial design is that of a randomized,
lacebo-controlled phase III add-on trial. In such a study, partic-
pants would be randomized to receive either the local standard
f care and the vaccine or the local standard of care and placebo.
hoosing an add-on trial design allows for women in either arm of
he study with risk factors for GBS transmission to their neonates
e.g. maternal fever in labor) to receive antibiotic treatment when
ndicated while also ensuring the scientiﬁc rigor of a randomized,
lacebo-controlled trial.
Yet speculation about the optimal design for a Phase III trial to
est vaccine efﬁcacy has raised ethical concerns for investigators
nd sponsors about what standard of care should be offered to par-
icipants in LMICs [1]. According to the most recent guidance from
he World Medical Association Declaration of Helsinki, “the ben-
ﬁts, risks, burdens and effectiveness of a new intervention must
e tested against those of the best proven intervention(s)” unless no
roven intervention exists or there are “compelling and scientiﬁ-
ally sound methodological reasons” to use something other than
he best proven therapy in determining the efﬁcacy or safety of a
ew intervention [20]. In addition, participants must not be sub-
ect to “additional risks of serious or irreversible harm as a result
f not receiving the best proven intervention” [20]. This guideline
peciﬁcally refers to the use of placebo in the control group, which
s generally uncontroversial in the case of an add-on trial since
articipants in the control arm receive both placebo and active
reatment [21]. However, the Declaration of Helsinki still raises
oncerns about the choice to provide the local standard rather than
est proven standard of care to all participants. Some may insist
hat maximizing the prospect of beneﬁt to enrolled mothers and
heir infants requires investigators to offer all trial participants the
orldwide best available standard of care—universal screening and
AP—in addition to either the vaccine or placebo. More neonates
ill likely be infected with GBS if the local standard of care, such
s in South Africa, is offered than if the mothers were provided
ith universal screening and IAP, as they are in some high-income
ountries. 33 (2015) 6396–6400
Others have argued that since the sustainability of universal
screening is not logistically or ﬁnancially feasible in LMICs, the
study would have more social and scientiﬁc value if it were imple-
mented in the context of the best local standard of care practice [1].
Moreover, from a sample size perspective, a Phase III trial may only
be feasible in LMICs like South Africa with a high burden of neona-
tal GBS disease and where screening-based intrapartum antibiotics
is not the standard of care [1]. In light of these concerns, would an
add-on trial design comparing vaccine to placebo in the context of
the local standard of care be ethically acceptable?
3. Ethical considerations
Determining the ethical acceptability of any study depends on
multiple factors [22]. To address questions about whether offer-
ing participants the local standard of care is ethically appropriate,
we wish to emphasize two  underlying worries at the heart of the
debate: the favorability of the study’s risk–beneﬁt ratio in light of
pregnancy-speciﬁc concerns and the potential exploitation of host
country research participants.
First, all studies should have a risk–beneﬁt ratio such that the
direct beneﬁts to participants or the overall beneﬁt to society justi-
ﬁes the foreseeable risks to participants [22]. In the case of maternal
vaccine research, as well as other clinical trials conducted dur-
ing pregnancy, beneﬁts and risks of trial participation for pregnant
women and their fetuses are of great concern. Assessing risk is par-
ticularly challenging in pregnancy, in large part due to a tendency
to focus on the fetal risks of an intervention while failing to con-
sider the maternal and fetal risks of failing to intervene [23]. Risks
of adverse events attributable to an intervention are also difﬁcult to
distinguish from background rates of fetal anomalies and adverse
perinatal outcomes that are unrelated to the intervention [24]. An
additional layer of complexity in risk assessment arises from the
complex physiologic connection between a mother and her fetus,
for threats to maternal health are likely to threaten fetal wellbeing
as well. A comprehensive assessment of research risks therefore
warrants consideration of maternal and fetal risks individually
and collectively. For example, administration of a maternal vac-
cine may  pose risks injection-related risks to the mother, speciﬁc
developmental risks for the fetus, and risks related to pregnancy
complications that may  affect the maternal–fetal pair. Yet focus-
ing solely on maternal and fetal risks is insufﬁcient to determine
whether a study’s risk level is ethically acceptable. These risks must
be assessed in relation to anticipated beneﬁts that the research may
offer to the mother, her fetus, or both.
Maternal vaccine trials aimed at primarily neonatal beneﬁt
are particularly interesting because they raise additional ethi-
cal questions about whether it is appropriate to pose risks to
a mother without corresponding maternal beneﬁt. Some may
worry that such trials are problematic because they expose a
mother to research risks without sufﬁcient direct beneﬁts to jus-
tify those risks. However, research that offers no direct beneﬁts
to participants can still be highly valuable for generating sci-
entiﬁc knowledge that will help others. International research
guidelines from the Council for International Organizations of Med-
ical Sciences (CIOMS) and the Common Rule of the United States
Code of Federal Regulations suggest that non-beneﬁcial research
is ethically permissible for competent and well-informed adults,
provided that study risks are reasonable in relation to anticipated
societal beneﬁts [25,26]. If it is ethically acceptable for an individ-
ual to join a clinical trial that offers no prospect of beneﬁt and
poses reasonable risks for altruistic reasons, then an even more
compelling case can be made for a mother who  wishes to partici-
pate in a vaccine trial offering the prospect of direct beneﬁt to her
neonate. When research risks have been assessed and minimized as
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uch as possible, guidelines from both CIOMS and Subpart B of the
nited States federal regulations allow for research that beneﬁts
he pregnant woman, beneﬁts her fetus, or contributes to impor-
ant generalizable knowledge that is relevant to pregnancy [25,26].
ince trade-offs can arise with interventions that are beneﬁcial for
ne member of the maternal–fetal dyad but harmful to the other,
he problem of maternal–fetal conﬂict is a potential worry. Yet
n practice, a pregnant woman must consider her own interests
nd protect the interests of her growing fetus when considering
hether to participate in a clinical trial. Her interests are aligned
ith the best interests of her fetus in many cases [24].
For a GBS vaccine efﬁcacy trial in the context of the local
tandard of care, ethical concerns about maternal exposure to risks
ithout maternal beneﬁts would not arise. Trial participation offers
he prospect of direct beneﬁt to both mothers and their fetuses, for
he vaccine may  reduce the risks of maternal infection and preg-
ancy complications such as preterm labor and stillbirth. Moreover,
aternal vaccine administration may  provide signiﬁcant indirect
aternal beneﬁts related to preventing serious neonatal illness.
ot only may  trial participation offer potential psychological ben-
ﬁts from carrying out parental obligations to protect one’s child
rom harm, but it can also offer indirect beneﬁts associated with
aring for a healthy rather than sick child after delivery. These col-
ective beneﬁts of study participation for both the mother and her
etus should be factored into the risk–beneﬁt analysis.
Determining whether the beneﬁts of study participation jus-
ify the risks in the case of a GBS vaccine efﬁcacy trial requires
areful assessment of available pre-clinical and clinical data to
nticipate the likely beneﬁts and risks to participants. Thus far, an
nitial investigational monovalent conjugate GBS vaccine appeared
o offer mothers and infants the potential for direct beneﬁt with low
isk [27]. Results showed sufﬁcient maternal immune response to
he vaccine, efﬁcient transplacental transfer of maternal antibodies,
ersistence of antibodies in the infants’ serum over 2 months, and
 reassuring safety proﬁle with no serious adverse events in Phase I
rials of the vaccine in healthy pregnant volunteers [27]. These data
ave been corroborated in Phase II trials of a trivalent GBS conju-
ate vaccine [28], indicating a risk–beneﬁt ratio with expected net
eneﬁts for individual participants exposed to the experimental
accine in a Phase III study.
Some may  argue that offering risk-based IAP to study partic-
pants as the local standard of care harms participants because
he incidence of invasive GBS disease in their infants will likely
e higher than would be the case if the study had offered univer-
al screening as the worldwide best available standard of care. Yet
here is an important distinction between investigators actively
arming participants and offering fewer beneﬁts to participants.
ince study participants would be exposed to the same level of
BS transmission whether or not they chose to enroll in a trial
ffering the local standard of care, investigators would not cause
ny additional harm by maintaining the local standard. Trial par-
icipation would not deprive participants of any treatment they
ould have otherwise received in routine clinical care. In fact,
he increased clinical surveillance of trial participants is likely to
mprove delivery of the local standard of care for those enrolled
n the study. This reasoning is consistent with the language in the
eclaration of Helsinki, which suggests that the ethical acceptabil-
ty of offering less than the best proven intervention depends in
art on whether participants would suffer any additional serious or
rreversible harm as a result [13]. In this case, providing the local
tandard of care would not cause additional harm.
On the other hand, a decision to offer a higher level of care than
he local standard could represent a beneﬁt to participants. While
nvestigators must ensure a favorable risk–beneﬁt ratio and may
ave a duty to provide some beneﬁts that can be readily offered to
articipants at little cost, they do not have an obligation to provide 33 (2015) 6396–6400 6399
beneﬁts that are overly burdensome, unattainable, or that under-
mine the scientiﬁc validity of the research. In this case, adopting
universal screening for trial participants would likely reduce the
burden of disease in the same way  that early-onset GBS disease
rates declined in European and North American countries that have
implemented universal screening and IAP [29]. Since a lower inci-
dence of disease to rates approaching 1 per 1000 live births would
necessitate the enrollment of close to 200,000 women to power
a placebo-controlled trial of a GBS vaccine, sample size consider-
ations alone could make such a trial impractical. One reason for
conducting such a trial in an LMIC like South Africa with a high bur-
den of neonatal GBS disease (roughly 3 cases per 1000 live births
which has remained consistent over two decades) is the ability to
demonstrate vaccine efﬁcacy with a reasonable sample size [1].
Hence, although a higher standard of care may  beneﬁt participants,
investigators and study sponsors must consider whether offering
such a beneﬁt would undermine the feasibility of conducting the
study.
Yet even when scientiﬁc validity and study feasibility provide
reasons for maintaining the local standard of care in a study, these
considerations are not sufﬁcient for determining the ethical accept-
ability of providing less than the worldwide best proven therapy in
LMIC settings. Ultimately, a feasible and scientiﬁcally-sound study
may  still be unethical if it lacks sufﬁcient social value and fails to
beneﬁt the community in which the research is conducted [22]. This
further ethical consideration involves the potential for exploitation.
Research funded by sponsors in high-income countries can
exploit low or middle income country populations who  host the
research when host country communities or participants bear an
unfair degree of risks and burdens, or high-income country spon-
sors receive an unfair level of beneﬁts from the research [22]. When
effective therapy exists and can be provided to participants, any
decision by investigators and sponsors to offer something less effec-
tive requires a sufﬁciently compelling justiﬁcation [20,21,30]. Some
bioethicists cautioned at the time of early HIV prevention studies,
which were designed to evaluate low-cost antiretroviral regimens
in low-income countries in which the standard of care amounted
to no treatment, that the ease of conducting a trial or desire to
reduce ﬁnancial burdens on sponsors did not constitute sufﬁciently
compelling justiﬁcation for providing no therapy or substandard
treatment [31]. Similar cautions would apply in this case.
However, if there are compelling reasons aside from cost con-
siderations to offer participants the local standard of care rather
than the best proven therapy and the host community is likely to
beneﬁt from the research, then it may  be possible to offer study
participants the local standard of care without increasing the risk
of exploitation. In this case, investigators can anticipate serious dif-
ﬁculties achieving an adequate sample size, obtaining valid results
that accurately reﬂect vaccine efﬁcacy in the local obstetrical care
setting, and completing the trial in a reasonable time frame if the
best proven therapy is offered. Since these concerns are likely mit-
igated if the study utilizes the local standard of care instead, such a
decision may  be justiﬁed provided that the community obtains fair
beneﬁts from such a study design. While beneﬁts may take many
forms depending on the needs of the community, one important
consideration of beneﬁt would be the likelihood that women  in the
community will actually receive the vaccine if the study demon-
strates vaccine efﬁcacy. Thus, providing the local standard of care
in a Phase III trial is unlikely to exploit the host community in South
Africa or other LMIC if the research is highly valuable and if the
infrastructure exists to incorporate maternal GBS vaccination into
the local system of antenatal care.In contrast, insisting on the worldwide best standard of care
may  actually increase the risk of exploitation. If the research spon-
sors were to recreate a setting that might reﬂect routine obstetrical
care in the United States or other high-income country with the
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nfrastructure for universal GBS screening, this may  ultimately
enerate results that are more generalizable to that high-income
ountry than to the South African or other LMIC context. In effect,
ponsors must choose between 2 scenarios: maintaining the best
roven standard of care for participants but little social value for
he host community, or a locally acceptable standard of care for par-
icipants and high social value for the host community. By failing
o consider the potential exploitation involved in the ﬁrst sce-
ario, concerns about exploitation could therefore be heightened
ather than minimized if sponsors impose universal screening stan-
ards on a host community when such standards are unsustainable
eyond the study period.
. Conclusion
In summary, there are compelling reasons to suggest that a
hase III study randomizing pregnant women to an investigational
BS vaccine or placebo along with the standard administration
f risk-based IAP could be a socially valuable study for evaluat-
ng whether the new GBS vaccine under development effectively
educes the incidence of both early and late-onset GBS disease in
MICs such as South Africa. Such an add-on trial design comparing
accine to placebo in addition to the current standard of care would
ikely yield useful scientiﬁc data in LMICS, be feasible to conduct
n the local practice setting, have a favorable risk–beneﬁt proﬁle
ased on available data, and presumably give a more accurate indi-
ation of vaccine efﬁcacy than a trial utilizing universal screening
hat would not be sustainable in LMIC practice. Based on these
onsiderations, using the local standard of care would be more eth-
cally appropriate than using a universal screening approach that
ould likely undermine the study feasibility and increase rather
han mitigate exploitation concerns.
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